May **22-23**, 2024 | **Munich, Germany** & Online (CEST) | **#VLbiomanufact**

REGISTER NOW

biomanufacturing:
continuous processing & digitalisation summit

Key Practical Learning Points:

- Optimising biopharmaceuticals process development, manufacturing, cost, and quality efficiency
- Applying emerging science and new technologies to optimise biopharma production
- Expediting the development of biopharmaceuticals by utilising intensified and continuous processing techniques
- Integrating continuous processing across upstream and downstream bioprocessing to foster seamless and uninterrupted production
- Applying intensified processing techniques to novel biologics, enabling efficient production and improving manufacturing capabilities
- Empowering scientific advancements and operational excellence in biomanufacturing with digitalisation and innovative approaches

Dr. Jens Smiatek, DE
Digital Lead at Development NCE
Boehringer Ingelheim Pharma GmbH & Co. KG

Dr. Ricardo Silva, PT
Senior Scientist
iBET - Instituto de Biologia Experimental e Tecnológica



Yi Li, US
Global Head, Downstream Drug Substance, Global MSAT
Sanofi

Dr. Touraj Eslami, AT
Automation Engineer
Austrian Centre of Industrial Biotechnology

Stephen Judd, IR
Process SME - Biologics/Cell & Gene Therapy
Arcadis | DPS Group Global

Rui Almeida, PT
Director, Product Lifecycle Management Services
Valgenesis

Dr. Dhanuka Wasalathanthri, US
Associate Director
Bristol Myers Squibb

Dr. Eliot Boulanger, BE
Head of Artificial Intelligence
Ovizio

Dr. Maximilian Krippl, AT
Head of Bioprocess Modelling Consulting
Novasign

Dr. Stephan Kirsch, AT
Director of Scientific Office Analytical Development
Novartis

Moritz von Stosch, CH
Chief Innovation Officer & Board Member
DataHow AG

Dr. Stefan Schmidt, CH
Chief Executive Officer
evitria AG

Dr. Edward Close, UK
Bioprocessing Practice Area Director
Siemens Digital Industries



Dr. Irina Ramos, US
Director - Bioprocess Technology and Engineering
AstraZeneca

Daniel Myatt, UK
Senior Scientist - Analytical
CPI

Dr. Francisca F. Gouveia, FR
Innovation Data & Digital Lead
Novartis



Dr. Dimitrios Lamprou, UK
Full Professor (Chair) of Biofabrication and Advanced Manufacturing & Director at **MSc Industrial Pharmaceutics | Queen's University Belfast (QUB)**

Fabian Stutz, CH
CEO
Pharmabotix AG

SPONSORSHIP SPEAKING & EXHIBITION OPPORTUNITIES AVAILABLE

VONLANTHEN CONFERENCES

May **22-23**, 2024 | **Munich, Germany** & Online (CEST) | **#VLbiomanufact**

REGISTER NOW

biomanufacturing:
continuous processing & digitalisation summit

Sponsorship-related questions to: **gabriela.vladimirova@vonlanthen-conferences.com**

Introduction

The biopharma industry operates under the constant drive to enhance productivity, reduce costs, and ensure product quality and consistency. To meet these demands, continuous biomanufacturing, process intensification and digitalisation have emerged as crucial solutions.

The Biomanufacturing: Continuous Processing & Digitalisation Summit delves into the complexities associated with the development and implementation of continuous and intensified processing in both upstream and downstream operations and leveraging digital capabilities.

While continuous bioprocessing offers remarkable advantages in improving productivity and facility utilisation for companies, digitalisation serves as a vital enabler for smarter bioprocessing, shedding light on the ongoing digital transformation within the bioprocessing industry.

Who Should Attend

Chief Executives, Directors, Vice Presidents, Department Heads, Leaders, and Managers specialising in:

- Advanced Process Control (APC)
- Analytics
- Artificial Intelligence (AI)
- Augmented Reality (AR) and Virtual Reality (VR)
- Automation and Digital
- Automation and Control
- Batch/Fed-Batch Processes
- Biopharmaceutical Lifecycle Management (BPLM)
- Bioprocessing
- Bioproduction
- Chemistry, Manufacturing, and Controls (CMC)
- Continuous Manufacturing (CM)
- Contract Manufacturing
- Data Analytics
- Data Management
- Digital Twins
- Digitalisation
- Digital Transformation
- Downstream Process (DSP)
- Engineering
- Facility Management
- Good Manufacturing Practices (GMP)
- In-Process Control (IPC)
- Industry 4.0
- Innovation Data and Digital
- Equipment Innovations
- High Throughput Process Development (HTPD)
- Machine Learning (ML)
- Manufacturing
- Manufacturing, Science, and Technology (MS&T)
- Modelling and Simulations
- Modular Facilities
- Multi-Purpose Facilities
- Novel Modalities (Biologics, Gene, Cell) and Vaccines
- Operational Excellence
- Pharmaceutical Lifecycle Managment (LCM)
- Plant/Site Management
- Process Analytical Technology (PAT)
- Process Engineering
- Process Science
- Quality
- Quality Assurance (QA)
- Quality Control (QC)
- Quality Risk Management
- Real-Time Process Control
- Regulatory
- Robotics and Automation
- Sensing Technologies
- Simulations Tools
- Supply Chain
- Upstream Process (USP)

VONLANTHEN CONFERENCES

biomanufacturing:
continuous processing & digitalisation summit

Schedule

DAY 1 | May **22**, 2024 | MUNICH & ONLINE (CEST) | #VLbiomanufact

08:15 Registration and Welcome Coffee

09:00 Opening by Chairman

09:10



Improving ATMP production by continuous integrated processing

- Raise product quality
- Enhance titers
- Reduce footprint
- Ease sterile operation
- Lower costs

Dr. Ricardo Silva, PT | Senior Scientist | iBET - Instituto de Biologia Experimental e Tecnológica

09:50 SPEED NETWORKING

10:20

Antibody manufacturing from micro to large scale: intensification approaches

- Antibodies and their derivatives are the major class of therapeutic proteins
- Their transition from discovery to development and commercial production requires careful adaptation of procedures to use the most appropriate solution for every step
- The common denominators are CHO cells, which represent the workhorse of all phases and affinity purification as tool for highly specific enrichment
- This presentation will discuss approaches for efficient manufacturing at all scales

Dr. Stefan Schmidt, CH | Chief Executive Officer | evitria AG

10:50 NETWORKING / COFFEE / EXHIBITION BREAK

11:20

Defining specifications in a risk-based control system

- A risk-based approach for specification setting
- How to adjust control critical and non-critical product quality attributes
- How to include patient-centricity in specification setting

Dr. Stephan Kirsch, AT | Director, Scientific Office Analytical Development | Novartis

11:50

Continuous biologics manufacture at CPI: Past, present, and future

- The Centre for Process Innovation (CPI) is part of the UK High Value Manufacturing Catapult (HVMC)
- CPI has been, and is currently, involved in several continuous biologics manufacturing projects
- Process analytical technology (PAT) is becoming increasingly important in biologics manufacturing
- Previous and current projects involving continuous manufacturing and the use of novel process analytical technologies (PATs)

Daniel Myatt, UK | Senior Scientist - Analytical | CPI

12:20 OPEN SPONSORSHIP OPPORTUNITIES

Sponsorship-related questions to:
gabriela.vladimirova@vonlanthen-conferences.com

13:20 BUSINESS LUNCH

14:10 NETWORKING/COFFEE BREAK

14:30

Continuous chromatography using advanced control strategies

- Enhancing productivity and efficiency: Advanced control strategies like MPC and EKF can revolutionise biopharmaceutical manufacturing by optimising productivity and efficiency
- Embracing sustainability: Applying advanced control strategies leads to minimising waste, reducing energy consumption, and optimising resource utilisation, promoting eco-friendly manufacturing
- Practical applications and case studies: Real-world examples of continuous chromatography systems utilising advanced control strategies provide insights, lessons learned, and future development possibilities

Dr. Touraj Eslami, AT | Automation Engineer | Austrian Centre of Industrial Biotechnology

VONLANTHEN CONFERENCES

15:00	 **The second-generation process development: Strategy, innovation, and regulatory considerations** • Business cost-benefit analysis and commercial process status are main drivers for second-generation process initiatives. Key strategies are based on a holistic understanding of process history, commercial production experiences, and up-to-date industrial peer practices • The development of second-generation process provides unique opportunities to incorporate next-gen process innovations such as cell engineering and continuous processing, novel raw materials, manufacturing digitalisation, and facility of future • The specific regulatory space (i.e. comparability) offers both challenges and opportunities with respect to the life cycle management of biomanufacturing Yi Li, US | Global Head, Downstream Drug Substance, Global MSAT | Sanofi
15:30	 **Fully integrated downstream process to enable next-generation manufacturing** Dr. Irina Ramos, US | Director - Bioprocess Technology and Engineering | AstraZeneca
16:00	NETWORKING / COFFEE BREAK
16:30	**Roadmap towards the next generation facility** Senior Consultant
17:00	 **Technical perspectives to accelerate manufacturing efficiency and embrace operational excellence** • Pre-requisites for effective implementation of digital solutions in commercial manufacturing • The "BioDigital" architecture: connecting the dots • Efficiency gains in upstream and downstream processing • Perspectives on how data and digital will reshape commercial biomanufacturing Dr. Francisca F. Gouveia, FR | Innovation Data & Digital Lead | Novartis
17:30	Q&A/PANEL DISCUSSION (All Speakers of the Day Are Invited) & CHAIRMAN'S CLOSING REMARKS
18:30	BUSINESS DINNER & NETWORKING

Upcoming Event

mRNA Process Development, Quality & Manufacturing Summit
December 05-06, 2023 | Vienna, Austria & Online | #VLmRNA

biomanufacturing: continuous processing & digitalisation summit

Schedule

DAY 2 | May **23**, 2024 | MUNICH & ONLINE (CEST) | #VLbiomanufact

08:00 Registration and Welcome Coffee

08:30 Opening by Chairman

08:40



- A journey into the wonderful world of emerging biopharmaceutical technologies
- Additive manufacturing (e.g., bioprinting and 4D printing) in biomanufacturing
- Microfluidics and lab-on-a-chip technologies for continuous and scalable approaches in nanomedicine
- Sustainable solution using emerging technologies

Dr. Dimitrios Lamprou, UK | Full Professor (Chair) of Biofabrication and Advanced Manufacturing & Director at MSc Industrial Pharmceutics | Queen's University Belfast (QUB)

09:10

Continuous manufacturing lifecycle management: An agile risk and data-driven framework

- Brief review of the current state of CM implementation
- Insights into lifecycle management and regulatory aspects (ICH Q9(R1) and ICHQ13 loop)
- Data/knowledge-centric approach to risk management to maximise CM full potential through a CPV program

Rui Almeida, PT | Director, Product Lifecycle Management Services | Valgenesis

09:40



Advanced scientific and explainable machine learning – From black box to white box models

- Background introduction: Advanced explainable and scientific machine learning for coupled and single unit operations
- Applications for different process steps: upstream processes, solubilisation, and drug product formulations
- Model analysis studies: Feature importance and predictive ensemble approaches
- Transfer learnings: Development of specific and generic machine learning models and usage of general concepts in terms of business value

Dr. Jens Smiatek, DE | Digital Lead at Development NCE | Boehringer Ingelheim Pharma GmbH & Co. KG

10:10

Transfer knowledge from project to project, reducing experimentation by hybrid modelling and transfer learning

- Transfer-learning methods enable understanding process behaviour across scales and products t accelerate process development
- Hybrid models combine data and process knowledge, reducing the number of experiments due to the knowledge incorporation
- How to move from traditional workflows to model-based development activities

Moritz von Stosch, CH | Chief Innovation Officer & Board Member | DataHow AG

10:40

Real-time microscopy for process control and optimisation

Dr. Eliot Boulanger, BE | Head of Artificial Intelligence | Ovizio

11:10 NETWORKING / COFFEE BREAK

11:40

Continuous bioprocessing digital process twins

- Capturing and deploying deep process knowledge in digital process twins across the process lifecycle to create value in R&D, engineering, and operations
- Mechanistic and hybrid modelling approaches in the biopharmaceutical industry
- Whole bioprocess modelling – End-to-end models of integrated continuous biomanufacturing processes to characterise and build robust process control strategies

Dr. Edward Close, UK | Principal Consultant | Siemens Digital Industries Software

12:10

Hybrid modelling and digital twins in bioprocess development, intensification, and control

- Currently, bioprocess development is based on design of experiments (DoE), which is time-consuming, leads to high cost of production, and limits the efficient use of existing process knowledge
- Time-resolved bioprocess models enable increased process understanding, process predictions, and online monitoring. In combination with smart experimental designs, these models can accelerate bioprocess development timelines and reduce development costs
- In this presentation, we'll showcase several use cases from both upstream and downstream and demonstrate the model's application in process optimisation, characterisation, monitoring, and for digital twins

Dr. Maximilian Krippl, AT | Head of Bioprocess Modeling Consulting | Novasign

VONLANTHEN CONFERENCES

12:30		**A machine-builider view on issues in cell and gene therapy manufacturing** • Robots and automation: Possible applications in CGT manufacturing • Modularity as the key: Sally - case study from inoculum preparation to cryovial filling **Fabian Stutz, CH** | CEO | Pharmabotix AG
12:50		**Process optimisation through inline dilution (ILD) and inline conditioning (ILC)** • ILD and ILC systems provide a closed and automated means of solution or process stream adjustment (ILD) or solution preparation (ILC) • Process technology that can be implemented at various stages in the process as part of developing semi-continuous/ continuous manufacturing operations • Use of novel approaches to minimise footprint and optimise the cleanroom grading strategy for modern facility designs • Process/manufacturing strategies to reduce capital cost, project schedules and operating costs, while improving sustainability **Stephen Judd, IR** | Process SME - Biologics/Cell & Gene Therapy | Arcadis | DPS Group Global
13:15		**Q&A/PANEL DISCUSSION (All Speakers of the Day Are Invited)**
13:15		**CHAIRMAN'S CLOSING REMARKS & THE END OF THE SUMMIT**
13:40		**BUSINESS LUNCH & NETWORKING**

Testimonials

What People Are Saying

Past
Attendee

The Summit was an incredibly informative and insightful event. The sessions on continuous processing and process intensification provided valuable strategies and practical approaches for optimizing biopharmaceutical manufacturing. The discussions on digitalization showcased the potential for transformative advancements in the industry. Truly a conference that keeps attendees at the forefront of innovation!

Past
Attendee

I thoroughly enjoyed attending the Summit. The sessions on continuous bioprocessing and intensified techniques provided valuable insights into maximising efficiency and productivity. The discussions on digital transformation were eye-opening, showcasing the power of data-driven decision-making in the biopharma industry. This summit was an exceptional platform for learning, networking, and staying abreast of the latest advancements.

Past
Attendee

The Summit was an outstanding event that brought together experts and thought leaders in the biopharma industry. The sessions on process optimization, cost-efficiency, and quality improvement were highly relevant and provided actionable takeaways. The focus on digitalisation and innovative approaches opened up new possibilities for enhancing our manufacturing processes. I am leaving this summit with a wealth of knowledge and valuable connections.

Dr. Jens Smiatek, DE | Digital Lead at Development NCE | Boehringer Ingelheim Pharma GmbH & Co. KG

Jens Smiatek has a PhD and habilitation in theoretical physics. He has taken various group leader positions in universities and research organisations, and his main biotechnological interests include modelling and advanced machine learning of coupled and single unit operations and formulation aspects. He is the author of more than 100 peer-reviewed articles with over 2600 citations (H-index 32). Since 2019, Jens has worked at Boehringer Ingelheim Pharma GmbH & Co. KG.

Dr. Stephan Kirsch, AT | Director, Scientific Office Analytical Development | Novartis

Stephan Kirsch is a versatile leader with interest in operational excellence, digitalisation and innovation, a scientific track record in mass spectrometry, and a focus on biologics drug substance development with major contributions to Zarzio and Beovu.



Dr. Ricardo Silva, PT | Senior Scientist | iBET - Instituto de Biologia Experimental e Tecnológica

Dr. Ricardo Silva graduated in 2008 with a degree in chemical and biochemical engineering from the Faculdade de Cincias e Tecnologia – Universidade Nova de Lisboa and obtained his PhD (2013) in chemical and biochemical engineering with a specialisation in process simulation and optimisation from the same university. In 2014, Ricardo was a senior scientist in the animal cell technology unit at iBET in the downstream process development lab and since 2019 has been in the late-stage R&D unit. Ricardo's current research topics are related to the development of efficient and integrated downstream processes for the purification of complex biotherapeutic targets, namely cell-based products, mAbs, virus-based biologics, recombinant proteins, and extracellular vesicles.

Moritz von Stosch, CH | Chief Innovation Officer & Board Member | DataHow AG

Dr. Moritz von Stosch is a thought leader in the area of digital process development and manufacturing and an author of more than 40 scientific publications, including the Book "Hybrid Modelling in Process Industries". He is the chief innovation officer at DataHow AG, and prior to joining DataHow he led the process systems biology and engineering centre of excellence at GSK vaccines, for which he received an Innovation Performance and Trust award and was nominated as a change catalyst.

Yi Li, US | Global Head, Downstream Drug Substance, Global MSAT | Sanofi

Yi Li has 20-plus years of industrial experience in leading and supporting clinical and commercial process development, process validation, global tech transfer and launch, IND and BLA filing, and post-approval life cycle management for various biologics and vaccines.

Dr. Stefan Schmidt, CH | Chief Executive Officer | evitria AG

Dr. Stefan R. Schmidt, MBA, currently is CEO at evitria AG, a company dedicated to antibody discovery services in Zürich. Previously Stefan led operations at BioAtrium AG, a joint venture of Lonza and Sanofi in Visp, Switzerland, as COO. Before that he held the position of CSO and other senior executive roles at Rentschler Biopharma (Germany) with overall responsibilities for biologics development and manufacturing. Before that, he was CSO at ERA Biotech in Barcelona, Spain, directing the company's R&D efforts based on fusion proteins. Prior to that, he worked at AstraZeneca in Sweden, where he led the unit of protein sciences within global protein science and supply as associate director. He started his leadership career 25 years ago at biotech companies in Munich, Germany, where he built up protein biochemistry teams for Connex and GPC-Biotech. He holds a PhD in biochemistry from the Julius Maximilians University in Wuerzburg, Germany, and an MBA from the University in Gävle, Sweden.

Dr. Touraj Eslami, AT | Automation Engineer | Austrian Centre of Industrial Biotechnology

As a post-doc and automation engineer at the Austrian Centre for Industrial Biotechnology (ACIB), Touraj Eslami specialised in downstream processing. Touraj is dedicated to enhancing biopharmaceutical manufacturing through advanced control strategies and quality by design (QbD) principles. Touraj is passionate about digitalisation and its potential to enhance productivity, efficiency, and sustainability.

Dr. Edward Close, UK | Principal Consultant | Siemens Digital Industries Software

Dr. Edward Close is practice area director for bioprocessing in Siemens Digital Industries Process Automation Software business. He has an engineering doctorate in biochemical engineering from University College London in collaboration with Pfizer. Edward has over 10 years' experience at Siemens leading the development and application of Siemens mechanistic and hybrid modelling solutions for bioprocessing to deliver value to across the process industries.

Stephen Judd, IR | Process SME - Biologics/Cell & Gene Therapy | Arcadis | DPS Group Global

Stephen Judd is a chartered chemical engineer and fellow of engineers Ireland. He is an experienced technical manager and principal process engineer with more than 15 years' experience in process engineering and facility design, mainly in biotech projects. He has an excellent mix of design office and field experience across a wide range of international clients with significant experience in process technology selection and facility design. He has experience across the full project life cycle from feasibility study to commissioning and qualification and now focusses on the early project phases developing the facility design and manufacturing philosophies. Stephen has significant experience with different process technologies across all parts of the manufacturing process for biologics, ATMP, and other novel therapies such as SPPS and mRNA vaccines. This includes selecting the optimum approach to suit the specific needs of the client/project with respect to hard-piped, single-use, or hybrid systems. Stephen has also authored or co-authored a number of technical papers including a paper on multi-modal facility design published in the ISPE PE Magazine. He is actively involved in the development of a number of ISPE guides currently in development relating to C&GT topics.

Rui Almeida, PT | Director, Product Lifecycle Management Services | Valgenesis

Rui Almeida leads ValGenesis' product lifecycle management consultancy group, offering a range of services where science and engineering are coupled in areas such as process lifecycle management, quality risk management, and CMC strategy. Rui has a licentiate degree in biological engineering and a master's degree in engineering management and nearly two decades of pharmaceutical industry experience, holding senior positions in technical services, quality assurance of IMP/commercial products, and project management in small and large pharmaceutical companies. Prior to joining ValGenesis, he served as PMO group leader in the services business segment of a CDMO.

Dr. Dhanuka Wasalathanthri, US | Associate Director | Bristol Myers Squibb

Dhanuka Wasalathanthri, PhD, is an associate director at Bristol Myers Squibb (BMS), where his main role is to serve as the strategy lead for process analytical technology (PAT), analytical automation, and digital capability at biologic development in Devens, MA (USA). He is a versatile analytical science professional with about 10 years of industry experience. His expertise features strategic development and implementation of PAT, high-throughput automation, and digital technologies for biopharmaceutical processing. Dhanuka represents BMS at several academic and industry consortia such as NIIMBL and BioPhorum, and he holds a PhD in analytical chemistry from the University of Connecticut (USA).

Dr. Francisca F. Gouveia, FR | Innovation Data & Digital Lead | Novartis

Francisca Gouveia is currently leading the innovation data and digital team at Novartis BioProduction Operations in Huningue, France. Francisca is a SME in biotech manufacturing and process analytical technologies (PAT) and leads the implementation of advanced data analytics and innovative technologies in manufacturing units. Francisca holds an MSc in pharmaceutical engineering (IST, University of Lisbon) and received her PhD from Copenhagen University, working on data-centric lifecycle management initiatives for new and legacy products.

Dr. Eliot Boulanger, BE | Head of Artificial Intelligence | Ovizio

Dr. Eliot Boulanger is the head of artificial intelligence at Ovizio, a company active in the field of holographic microscopy for cell culture monitoring. Prior to that, he was leading the digital strategy of the biotech department of UCB biopharma. He holds a PhD in computational chemistry from the Max-Planck-Institut für Kohlenforschung and a post-doc in biophysics from the University of Chicago.



Dr. Dimitrios Lamprou, UK | Full Professor (Chair) of Biofabrication and Advanced Manufacturing & Director at MSc Industrial Pharmceutics | Queen's University Belfast (QUB)

Dimitrios Lamprou (PhD, MBA) is a full professor (chair) of biofabrication and advanced manufacturing, and a director at MSc industrial pharmaceutics at Queen's University Belfast (QUB). He is also the chair at United Kingdom and Ireland Controlled Release Society (UKICRS) and the chair of the Academy of Pharmaceutical Sciences (APS) emerging technologies focus group. Dimitrios is the author of over 150 peer-reviewed publications, has over 350 conference abstracts, has given over 150 invited talks in institutions and conferences across the world, and has secured funding of more than £4M. Dimitrios has been recognised as a world leader in 3D printing and microfluidics. PubMed-based algorithms placed him in the top 0.088% of scholars in the world writing about 3D printing and in the top 0.071% of scholars in the world writing about microfluidics in the past 10 years. Moreover, PubMed-based algorithms placed him in the top 0.63% of scholars in the world writing about nanofibers. Dimitrios has also twice been named in Stanford University's list of the world's top 2% scientists (2021 and 2022) for his research in pharmaceutics and biomedical engineering. His research and academic leadership have been recognised in a range of awards, including the Royal Pharmaceutical Society Science Award and the Scottish Universities Life Sciences Alliance Leaders Scheme Award.

Daniel Myatt, UK | Senior Scientist - Analytical | CPI

Daniel Myatt is a senior scientist in the analytical group at the Centre for Process Innovation (CPI, UK). He has a degree in biochemistry and a PhD in biophysics from the University of Manchester (UK). He has experience with a variety of biochemical and biophysical techniques gained from working in biopharma, academia, and at large-scale facilities.

Dr. Maximilian Krippl, AT | Head of Bioprocess Modeling Consulting | Novasign

Maximilian is the head of bioprocess modelling consulting at Novasign, where he is responsible for modelling projects for upstream and downstream processes. Leveraging his expertise in mathematical modelling, he collaborates with clients to design and accelerate process development and predict and control bioprocess performance. Maximilian holds a master's degree in technical chemistry from TU Wien and earned his PhD from the prestigious University of Natural Resources and Applied Life Sciences in Vienna, Austria, for which he was awarded the Award of Excellence from the Austrian Ministry of Education, Science and Research.

Fabian Stutz, CH | CEO | Pharmabotix AG

Fabian Stutz is the CEO and head of sales with Pharmabotix AG, a company that provides clients with innovative robotics and automation solutions for the pharmaceutical industry. From building an effective team to maintaining a large customer network, he is adept at driving business development while delivering exceptional service to customers with a direct communications approach. Fabian is passionate about trying new ideas and providing honest feedback on feasibility to ensure customer satisfaction.

biomanufacturing: continuous processing & digitalisation summit

Registration Form

May **22-23**, 2024 | **Munich** & Online (CEST)

CHOOSE YOUR PACKAGE

Attendee packages	Register by December 15	Standard Price
☐ In person - *Access to the speakers' presentations, daily networking and refreshment breaks*	€1095 (save **€900**)	€1995
☐ Group Booking +3 - *Access to the speakers' presentations, daily networking and refreshment breaks*	€995 (save **€800**)	€1795
☐ Online package - *Access to the full live event and the live event recording*	€1095 (save **€900**)	€1995

Promotional Packages		Standard Price
☐ Partnering [fixed price] - *Company awareness on the Vonlanthen website, brochure, SM Banner, pre/post-event communications, and during the event*		€695
☐ Promo materials [fixed price] - *Distribution of your company's promotional materials to the attendees*		€595

→ *Hotel accommodation & travel costs are not included in the registration fee*

To register for the Summit, please provide the details below. ** Required fields*

1

Name*: Surname*:

Position*:

E-mail*:

Special dietary requirements: ☐ *Vegetarian* ☐ *Gluten-free* ☐ *Other (please specify)* _____

2

Name*: Surname*:

Position*:

E-mail*:

Special dietary requirements: ☐ *Vegetarian* ☐ *Gluten-free* ☐ *Other (please specify)* _____

3

Name*: Surname*:

Position*:

E-mail*:

Special dietary requirements: ☐ *Vegetarian* ☐ *Gluten-free* ☐ *Other (please specify)* _____

4

Name*: Surname*:

Position*:

E-mail*:

Special dietary requirements: ☐ *Vegetarian* ☐ *Gluten-free* ☐ *Other (please specify)* _____

Company* (for corporate billing) / Name* (for individual billing)

Address

City / Country*

Phone Number*

VAT Number for Company* (only for EU)

Post code*

Date

Payment method

- ○ Wire transfer
- ○ Credit card

Invoice billing information*

- ○ Corporate
- ○ Individual

☐ By sending this form, I confirm that I have read and accepted the **Terms and Conditions**. To view the full Terms & Conditions and Privacy Policy terms, visit: vonlanthenevents.com/en/terms-conditions

To complete the registration process, fill out the form and send it to: fin.department@vonlanthen-conferences.com

Upon receiving the registration form, you will receive an invoice by email.

Sponsorship packages	Virtual Presentation ☐ €1,999	Presentation ☐ €2,999	Table Top ☐ €3,999	Bronze ☐ €5,999	Silver ☐ €6,999	Gold ☐ €8,999	Platinum ☐ €11,999
People attending	1	1	1	2	2	3	4
Logo on conference website, program, and pre/post-event communication activities	◆	◆	◆	◆	◆	◆	◆
Discount on additional passes	10%	10%	10%	15%	20%	30%	40%
Promotional material distribution (provided by sponsor)	◆	◆	◆	◆	◆	◆	◆
Recognition on Vonlanthen Group's SM channels				◆	◆	◆	◆
Ad placed in final conference program				1/4 Page	1/4 Page	1/2 Page	Full Page
Recognition in chairman's opening address				◆	◆	◆	◆
Speaking slot	20 min	20 min			30 min	40 min	60 min
Table Top			◆	◆	◆	◆	
Host own seminar/workshop within the conference							40 min
Recognition in press release						◆	◆
Exhibition Stand with monitor for video presentations							◆

**For more information on the packages and to discuss your sponsorships requirements, please contact: gabriela.vladimirova@vonlanthen-conferences.com*